"Promotion Steering Committee" In Planning Stage, FDA Ad Division Head Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The group will include senior officials from the drug and biologics review centers and reps from the chief counsel's and commissioner's offices, CDER ad division director Abrams says. CDER has issued eight warning letters this year; omission of risk information and unproven claims are most common violations.
You may also be interested in...
FDA Inter-Center Ad Group Launches Prior To Departure Of Chief Counsel Troy
The Promotion Steering Committee is expected to develop guidance documents that bring transparency to FDA’s oversight of product advertising and reflect common standards for promotion across product areas, Troy says.
FDA Inter-Center Ad Group Launches Prior To Departure Of Chief Counsel Troy
The Promotion Steering Committee is expected to develop guidance documents that bring transparency to FDA’s oversight of product advertising and reflect common standards for promotion across product areas, Troy says.
FDA Cites J&J Duragesic Promotion For Misleading Safety Profile
Reports from a national drug abuse surveillance database are not sufficient basis for comparative safety claims between the Duragesic patch and other pain agents, FDA says. The agency asks J&J to devise a corrective action plan for a violative professional file card that was distributed beginning in 2003.